T Lymphocyte Subsets in Ulcerative Colitis
NCT06352515 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 80
Last updated 2024-04-29
Summary
1. Study the distribution of peripheral blood T lymphocyte subsets among ulcerative colitis patients.
2. Correlation of T-cell subsets to therapeutic response/ disease activity.
3. Assess the value of circulating IgG anti-Integrin αvβ6 in UC.
Conditions
Interventions
- DIAGNOSTIC_TEST
-
Flow cytometry
flow cytometry to study distribution of T lymphocyte subsets in ulcerative colitis patients
Sponsors & Collaborators
-
Assiut University
lead OTHER
Principal Investigators
-
Nadia Abdelwahab · Assiut University
-
Asmaa Bakr · Assiut University
-
Tarek Elmelegy · Assiut University
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-06-01
- Primary Completion
- 2026-06-01
- Completion
- 2027-06-01
More Related Trials
-
Cross Sectional Study of Vaccine Antibody Response in Inflammatory Bowel Disease Patients
NCT02434133 ·Status: COMPLETED
-
Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis
NCT06453317 ·Status: RECRUITING ·Phase: PHASE2
-
Hematological Indices and Fecal Calprotectin Predict Histological Remission in Ulcerative Colitis
NCT04818788 ·Status: UNKNOWN
-
Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis
NCT02632175 ·Status: COMPLETED ·Phase: PHASE3
-
Postoperative REcurrence and DynamICs of T Cell Subsets in Crohn's Disease
NCT02770495 ·Status: COMPLETED ·Phase: PHASE3
-
A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bowel Disease, Who Have Been Treated With Adalimumab and Who Developed Hepatosplenic T-Cell Lymphoma
NCT02087878 ·Status: WITHDRAWN
-
Transperineal Ultrasound for Assessing and Predicting Response in Hospitalized Patients with a Flare of Ulcerative Colitis
NCT06496516 ·Status: NOT_YET_RECRUITING
-
The Innate Immune System and Inflammatory Bowel Disease
NCT00516776 ·Status: COMPLETED
-
Immunological Characteristics of Patients With PID and IBD
NCT03148028 ·Status: UNKNOWN
-
Critical State of "Remission-Recurrence" of Ulcerative Colitis
NCT06694883 ·Status: RECRUITING
-
NKT Role in the Regulation of the Inflammatory Bowel Disease
NCT02884557 ·Status: COMPLETED ·Phase: NA
-
Interactions Between Immune Cells of Intestinal Mucosa or Peripheral Blood With the Extracellular Matrix in Inflammatory Bowel Disease (IBD)
NCT00915044 ·Status: UNKNOWN
-
Rituximab in Active Ulcerative Colitis
NCT00261118 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Neutrophil to Lymphocyte Ratio in Inflammatory Bowel Disease
NCT04558658 ·Status: UNKNOWN
-
A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
NCT02819635 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Prognosis in UC After First Biological
NCT05530122 ·Status: COMPLETED
-
The Validity of Novel Non-invasive Inflammatory Markers for Monitoring of Patients With Ulcerative Colitis
NCT04670250 ·Status: UNKNOWN
-
A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)
NCT01804166 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Clinical Course of Newly Diagnosed Moderate to Severe Ulcerative Colitis in Korea
NCT02229344 ·Status: COMPLETED
-
Upper Endoscopy in Ulcerative Colitis Patients in Assiut University
NCT06092593 ·Status: NOT_YET_RECRUITING
-
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
NCT06257875 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Clinical Outcome of Treatment of Ulcerative Colitis in Adult
NCT06143163 ·Status: NOT_YET_RECRUITING
-
Prevalence of Graves Disease in Patients With Ulcerative Colitis
NCT03324334 ·Status: UNKNOWN
-
Evaluation of Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of Bertilimumab in Patients With Active Moderate to Severe Ulcerative Colitis
NCT01671956 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis
NCT03653026 ·Status: COMPLETED ·Phase: PHASE3